Plural Phosphorus Atoms Bonded Directly To The Same Chalcogen In A Chain (e.g., Pyrophosphates, Polyanhydrides Of Phosphorus Acids, Etc.) Patents (Class 536/26.21)
-
Patent number: 11851687Abstract: Provided herein are modified Archaeal family B polymerases derived from species of the Archaeal microorganism Pyrococcus that exhibit improved incorporation of nucleotide analogues utilized in DNA sequencing.Type: GrantFiled: March 19, 2021Date of Patent: December 26, 2023Assignee: Singular Genomics Systems, Inc.Inventors: Souad Naji, Eli N. Glezer, Youngjin Cho, Zachary Terranova, Abrehet Abdu
-
Patent number: 11028118Abstract: The invention provides a process for the preparation of nicotinamide mononucleotide having formula (I): The method involves the protection of nicotinamide riboside by ketalization, followed by phosphorylation and then deprotection to provide nicotinamide mononucleotide.Type: GrantFiled: March 16, 2020Date of Patent: June 8, 2021Assignee: Cornell UniversityInventors: Anthony Sauve, Farheen Sultana Yang Mohammed
-
Patent number: 10590160Abstract: The invention provides a process for the preparation of nicotinamide mononucleotide having formula (I): The method involves the protection of nicotinamide riboside by ketalization, followed by phosphorylation and then deprotection to provide nicotinamide mononucleotide.Type: GrantFiled: March 24, 2016Date of Patent: March 17, 2020Assignee: CORNELL UNIVERSITYInventors: Anthony Sauve, Farheen Sultana Mohammad
-
Patent number: 10493091Abstract: [Problem] Provided is a method for easily and stably storing crystals of P1,P4-bis(5?-uridyl)tetraphosphate for a long term. [Solution] A method for storing packed crystals of P1,P4-bis(5?-uridyl)tetraphosphate or a pharmaceutically acceptable salt thereof, wherein one of the following storage conditions (1) to (3): (1) a storage temperature of 0° C. or more and less than 25° C.; (2) a storage temperature of 25° C. or more and less than 40° C. and a crystal pH of 4.5 to 8.0; and (3) a storage temperature of 40° C. or more and less than 60° C. and a crystal pH of 5.0 to 6.4 is selected and the crystals of P1,P4-bis(5?-uridyl)tetraphosphate or the pharmaceutically acceptable salt thereof are stored under the selected condition.Type: GrantFiled: June 28, 2016Date of Patent: December 3, 2019Assignee: Yamasa CorporationInventors: Yusuke Ohba, Kentaro Miyoshi, Fumitaka Kano
-
Publication number: 20150140561Abstract: The present invention provides deoxynucleoside tri- or tetraphosphate comprising a 3? nitrate and a detectable label covalently bound to the oxygen atom of an oxymethyl or oxyallyl or oxypropargyl substitution of a nucleobase. Such compounds provide new possibilities for future Sequencing by Synthesis technologies.Type: ApplicationFiled: November 17, 2014Publication date: May 21, 2015Inventors: Frank Bergmann, Dieter Heindl, Jessica Steger-Domandl
-
Patent number: 8981078Abstract: An agent for inhibiting translesion DNA replication comprises a non-natural adenine ribose analog represented by those as set forth in FIG. 1.Type: GrantFiled: January 4, 2012Date of Patent: March 17, 2015Assignee: Case Western Reserve UniversityInventors: Anthony J. Berdis, Irene Lee, Xuemei Zhang
-
Publication number: 20150045319Abstract: This disclosure relates to uridine diphosphate (UDP) derivatives, compositions comprising therapeutically effective amounts of those UDP derivatives and methods of using those derivatives or compositions in treating disorders that are responsive to ligands, such as agonists, of P2Y6 receptor, e.g., neuronal disorders, including neurodegenerative disorders (e.g., Alzheimer's disease) and traumatic CNS injury, as well as pain.Type: ApplicationFiled: July 3, 2014Publication date: February 12, 2015Inventors: Philip G. Haydon, Jinbo Lee, Jinghui Dong, Stephen Moss, Raquel Revilla-Sanchez
-
Patent number: 8889125Abstract: The present invention relates to a method of treatment and/or ameliorating the symptoms of Huntington's disease comprising the step of administering an effective amount of adenosine triphosphate, co-carboxylase, nicotinamide, and cyanocobalamin in a physiologically acceptable carrier to an individual in need thereof. Preferably, the administration is via intramuscular injection.Type: GrantFiled: March 15, 2013Date of Patent: November 18, 2014Assignee: Genix Therapeutics Group, LLCInventor: Ragab El-Rashidy
-
Publication number: 20140178878Abstract: The present application discloses a labeled nucleotide comprising a label attached via a linker, wherein said labeled nucleotide has the formula wherein R1 is a residue with a negative net charge, preferably selected from the group consisting of a phosphate group, and a sulphate group; wherein R2, R3 and R4 are independently selected from the group consisting of H2, OH2, and O; wherein “n” is an integer between 0 and 16; wherein “a” is an integer between 1 and 10; wherein SP is absent or a spacer; wherein X is said label; and wherein Y is a nucleotide or nucleoside. Furthermore, oligonucleotides comprising a labeled nucleotide according to the present invention and the use as a primer in amplification based methods is disclosed herein.Type: ApplicationFiled: May 4, 2012Publication date: June 26, 2014Inventors: Daniel Müller, Francesca Di Pasquale
-
Publication number: 20140162972Abstract: This disclosure relates to prodrugs of uridine diphosphate (UDP) derivatives, compositions comprising therapeutically effective amounts of those prodrugs of the UDP derivatives and methods of using those prodrugs or compositions in treating disorders that are responsive to ligands, such as agonists, of P2Y6 receptor, e.g., neuronal disorders, including neurodegenerative disorders (e.g., Alzheimer's disease, Parkinson's disease) and traumatic CNS injury, pain, Down Syndrome (DS), glaucoma, and inflammatory conditions.Type: ApplicationFiled: September 27, 2013Publication date: June 12, 2014Applicant: Tufts UniversityInventors: Philip G. Haydon, Jinbo Lee
-
Patent number: 8742094Abstract: The invention relates to a method for producing phosphate-bridged nucleoside conjugates. In the method, a cyclosaligenyl nucleotide is produced first, to which a linker is added, which is used to perform the immobilization on a solid phase. A subsequent reaction with corresponding nucleophiles results in the desired phosphate-bridged nucleoside conjugates, which can then again be cleaved from the solid phase-bound linker.Type: GrantFiled: May 6, 2010Date of Patent: June 3, 2014Assignee: Universitaet HamburgInventors: Chris Meier, Viktoria Caroline Tonn
-
Publication number: 20140080127Abstract: The present invention provides heteroaryl functionalized cyanine dyes including a reactive functional moiety, or which are conjugated to a carrier molecule.Type: ApplicationFiled: November 20, 2013Publication date: March 20, 2014Applicant: Pacific Biosciences of California, Inc.Inventors: Stephen YUE, Gene Shen, Wei-Chuan Sun
-
Patent number: 8674086Abstract: Embodiments of the invention provide non-natural bifunctional nucleotides having both nuclease resistance and nucleic acid synthesis blocking properties and methods of sequencing nucleic acids that employ non-natural bifunctional nucleic acids. Additional embodiments provide non-natural oligonucleotides and methods for sequencing nucleic acids using the non-natural oligonucleotides. Methods according to embodiments of the invention employ electronic detection and fluorescent detection of nucleic acid sequencing reactions.Type: GrantFiled: June 25, 2010Date of Patent: March 18, 2014Assignee: Intel CorporationInventors: Jianquan Liu, Xing Su, Kai Wu
-
Publication number: 20140045798Abstract: The present invention provides a compound of Formula Ia, wherein R1 is H or phosphate and the double bond is between N1 and C1 or between N2 and C1; R2 is a mitochondrial targeting moiety; R3 an alkyl, alkylaryl, alkylheteroaryl spacer group, a cleavable linker, or absent; R4 is H or an alkyl, aryl, or heteroaryl group; and R5 is alkyl, aryl, or heteroaryl; or N1 C1, and N3 together form a heterocyclic ring containing at least 5 atoms, wherein N1, N3, and R1-R5 are as defined above, or N3 and R5 together form a heterocyclic ring containing at least four atoms; or a pharmaceutically acceptable salt or prodrug thereof.Type: ApplicationFiled: October 18, 2013Publication date: February 13, 2014Applicant: Gencia CorporationInventor: Shaharyar Khan
-
Patent number: 8603741Abstract: Methods, Compositions, and Systems are provided for nucleic acid sequencing where the sequential incorporation of nucleotides uses two distinct chemical steps. A plurality of nucleotide analogs, each having a labeled leaving group at its 3? hydroxyl can be sequentially added to a growing strand in the presence of a selective cleaving activity that cleaves the 3? hydroxyl leaving group preferentially after it has been incorporated. The selective cleaving agent can comprise an exonuclease activity, and the exonuclease activity can be a polymerase-associated exonuclease activity. Nucleotide analogs having labels on both a cleavable polyphosphate portion and on a 3? hydroxyl leaving group can provide signals characteristic of nucleotide analog incorporation. Systems having illumination optics, collection optics, and substrates observe signals from the labels as they are being incorporated into a growing nucleic acid strand, allowing for the sequencing of template nucleic acids.Type: GrantFiled: February 8, 2011Date of Patent: December 10, 2013Assignee: Pacific Biosciences of California, Inc.Inventors: Robin Emig, Lei Jia, Jeremiah Hanes, Lubomir Sebo
-
Publication number: 20130324495Abstract: The invention provides particular uridine di- and tri-phosphate derivatives, and pharmaceutical compositions thereof. These compounds are useful for treatment of diseases, disorders and conditions modulated by P2Y6 receptors, and particularly for lowering intraocular pressure and thereby treating ocular hypertension and/or glaucoma.Type: ApplicationFiled: December 1, 2011Publication date: December 5, 2013Applicants: UNIVERSIDAD COMPLUTENSE DE MADRID, BAR-ILAN UNIVERSITYInventors: Bilha fischer, Jesus Jeronimo Pintor, Shay Elyahu, Tamar Ginsburg-Shmuel
-
Patent number: 8575127Abstract: The invention features compounds of formula I and methods of their use as antiplatelet and antithrombotic compounds: H/N=Q?2OOOO?Q2-N, HR6/NIf)(^XMO-M??OM°?X1MQ?)r(^rfHOOHHOOQHiN?iR2 Formula (I).Type: GrantFiled: November 20, 2009Date of Patent: November 5, 2013Assignee: GLSynthesis Inc.Inventors: Ivan Borissov Yanachkov, George Edward Wright
-
Publication number: 20130264207Abstract: This disclosure is related to a method of sequencing a single-stranded DNA using deoxynucleotide polyphosphate analogues and translocation of tags from incorporated deoxynucleotide polyphosphate analogues through a nanopore.Type: ApplicationFiled: December 16, 2011Publication date: October 10, 2013Inventors: Jingyue Ju, Shiv Kumar, Zengmin Li, Chuanjuan Tao, Minchen Chien, James J. Russo, Sergey Kalachikov, Ken Shepard, Jacob Karl Rosenstein
-
Patent number: 8546557Abstract: The invention provides compounds and methods for making adenosine-ribofuranoside tetraphosphate compounds. The compounds are contemplated to have activity at the P2Y receptor and may be used in the treatment of medical disorders such as cystic fibrosis and upper respiratory disorders.Type: GrantFiled: February 13, 2009Date of Patent: October 1, 2013Assignee: Microdose Therapeutx, Inc.Inventors: Carmen M. Baldino, Dan P. Cook, Shomir Ghosh, Lazlo Varady, Thomas Andreas Waldbach, Zhongguo Wang
-
Publication number: 20130252919Abstract: This disclosure relates to uridine diphosphate (UDP) derivatives, compositions comprising therapeutically effective amounts of those UDP derivatives and methods of using those derivatives or compositions in treating disorders that are responsive to ligands, such as agonists, of P2Y6 receptor, e.g., neuronal disorders, including neurodegenerative disorders (e.g., Alzheimer's disease) and traumatic CNS injury, as well as pain.Type: ApplicationFiled: March 8, 2013Publication date: September 26, 2013Applicant: TUFTS UNIVERSITYInventors: Philip Haydon, Jinbo Lee, Jinghui Dong, Stephen Moss, Raquel Revilla-Sanchez
-
Publication number: 20130225519Abstract: A nucleoside compound having activity against hepatitis C virus is disclosed.Type: ApplicationFiled: February 25, 2013Publication date: August 29, 2013Applicant: GILEAD PHARMASSET LLCInventor: GILEAD PHARMASSET LLC
-
Publication number: 20130184160Abstract: The present disclosure encompasses oligonucleotide aptamers selectively binding a target glycosylated polypeptide or protein, and having biased affinity for the glycan through a boronic acid linked to a nucleosidic base of a nucleotide(s). The disclosure further encompasses methods for isolating an aptamer(s) selectively binding a target glycosylated polypeptide, where, from a population of randomized oligonucleotides that have at least one nucleotide having a boronic acid label linked to a base, is selected a first subpopulation of aptamers binding to the target glycosylated polypeptide or protein. This subpopulation is then amplified without using boronic acid-modified TTP, and amplification products not binding to a target glycosylated polypeptide or protein are selected. The second subpopulation of aptamers is then amplified using boronic acid-modified TTP to provide a population of boronic acid-modified aptamers capable of selectively binding to a glycosylation site of a target polypeptide or protein.Type: ApplicationFiled: July 17, 2008Publication date: July 18, 2013Inventors: Binghe Wang, Minyong Li, Zhen Huang, Na Lin
-
Publication number: 20130072462Abstract: The present invention provides a compound of Formula 1a, wherein R1 is H or phosphate and the double bond is between N? and C? or between N2 and C1; R2 is a mitochondrial targeting moiety; R3 an alkyl, alkylaryl, alkylheteroaryl spacer group, a cleavable linker, or absent; R4 is H or an alkyl, aryl, or heteroaryl group; and R5 is alkyl, aryl, or heteroaryl; or N? C?, and N3 together form a heterocyclic ring containing at least 5 atoms, wherein N1, N3, and R1-R5 are as defined above, or N3 and R5 together form a heterocyclic ring containing at least four atoms; or a pharmaceutically acceptable salt or prodrug thereof.Type: ApplicationFiled: August 17, 2012Publication date: March 21, 2013Applicant: Gencia CorporationInventor: Shaharyar Khan
-
Publication number: 20130045475Abstract: This disclosure provides novel reversibly terminated ribonucleotides which can be used as a reagent for DNA sequencing reactions. Methods of sequencing nucleic acids using the disclosed nucleotides are also provided.Type: ApplicationFiled: October 23, 2012Publication date: February 21, 2013Applicant: ALERE SAN DIEGO, INC.Inventor: Alere San Diego, Inc.
-
Patent number: 8349812Abstract: Immunostimulatory oligoribonucleotides (ORN) featuring 5?-triphosphates and various 5?-triphosphate analogs are provided. Also provided are physiologically acceptable salts of the immunostimulatory ORN and pharmaceutical compositions containing the immunostimulatory ORN of the invention. ORN of the invention are useful as adjuvants and can be combined with an antigen to promote an antigen-specific immune response. ORN of the invention are also particularly useful for promoting a Th1-type immune response. Also provided are methods of use of the compounds and pharmaceutical compositions of the invention to enhance an immune response in a subject, as well to treat a number of conditions including cancer, infection, allergy, and asthma, and to vaccinate a subject against an antigen.Type: GrantFiled: October 30, 2008Date of Patent: January 8, 2013Assignee: AdiuTide Pharmaceuticals GmbHInventors: Harald Debelak, Eugen Uhlmann
-
Patent number: 8304529Abstract: Novel cap analogs which are easily synthesized, resulting in high levels of capping efficiency and transcription and improved translation efficiencies are provided. Such caps are methylated at the N7 position of one or both guanosines of the dinucleotide cap as well as at the 3? position on the ribose ring. Substituent groups on the ribose ring also result in the cap being incorporated in the forward orientation. Also provided are methods useful for preparing capped analogs and using mRNA species containing such analogs are also contemplated herein, as well as kits containing the novel cap analogs.Type: GrantFiled: July 10, 2007Date of Patent: November 6, 2012Assignee: Life Technologies CorporationInventors: Anilkumar R. Kore, Muthian Shanmugasundaram
-
Publication number: 20120220922Abstract: The present invention describes Photolabile Compounds methods for use of the compounds. The Photolabile Compounds have a photoreleasable ligand, which can be biologically active, and which is photoreleased from the compound upon exposure to light. In some embodiments, the Photolabile Compounds comprise a light antenna, such as a labeling molecule or an active derivative thereof. In one embodiment, the light is visible light, which is not detrimental to the viability of biological samples, such as cells and tissues, in which the released organic molecule is bioactive and can have a therapeutic effect. In another embodiment, the photoreleasable ligand can be a labeling molecule, such as a fluorescent molecule.Type: ApplicationFiled: December 23, 2011Publication date: August 30, 2012Applicants: Universidad de Buenos Aires, THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORKInventors: Rafael YUSTE, Roberto Etchenique, Luis Baraldo
-
Publication number: 20120190620Abstract: The present invention discloses methods to identify targets, pathways and molecules regulating purinosomes and their uses for treating pathophysiological disorders associated with purinosomes. Disclosed are methods related to both label-free cellular assays and fluorescence imaging to confirm the regulatory roles of various targets and molecules in purinosome dynamics. Disclosed are methods to classify molecules and the uses of these molecules for different indications. Specifically, the purinosome-disrupting molecules can be used for improved prevention and treatment of cancer development.Type: ApplicationFiled: July 18, 2011Publication date: July 26, 2012Inventors: Stephen Benkovic, Ye Fang, Songon An, Florence Verrier
-
Publication number: 20120165515Abstract: The present invention provides nucleoside compounds and certain derivatives thereof which are inhibitors of RNA-dependent RNA viral polymerase. These compounds are inhibitors of RNA-dependent RNA viral replication and are useful for the treatment of RNA-dependent RNA viral infection. They are particularly useful as inhibitors of hepatitis C virus (HCV) NS5B polymerase, as inhibitors of HCV replication, and/or for the treatment of hepatitis C infection. The invention also describes pharmaceutical compositions containing such nucleoside compounds alone or in combination with other agents active against RNA-dependent RNA viral infection, in particular HCV infection. Also disclosed are methods of inhibiting RNA-dependent RNA polymerase, inhibiting RNA-dependent RNA viral replication, and/or treating RNA-dependent RNA viral infection with the nucleoside compounds of the present invention.Type: ApplicationFiled: February 2, 2007Publication date: June 28, 2012Inventors: Balkrishen Bhat, Anne B. Eldrup, Thazha P. Prakash, Phillip Dan Cook, Robert L. LaFemina, Amy L. Simcoe, Carrie A. Rutkowski, Mario A. Valenciano
-
Publication number: 20120135092Abstract: Compounds for modulating RecA protein activity are provided. In some embodiments, the compounds modulate RecA activity by interfering with assembly of monomeric RecA protein subunits into a nucleoprotein filament. In some embodiments, the compounds modulate RecA activity by interfering with adenosine triphosphate hydrolysis by the RecA protein. In some embodiments, the compound is a N6-modified adenosine compound. Methods of screening for and methods of using the compounds are also provided.Type: ApplicationFiled: March 14, 2008Publication date: May 31, 2012Inventor: Scott Fain Singleton
-
Publication number: 20120122811Abstract: The present disclosure relates to the use and methods of manufacture of bicyclic nucleosides and nucleotides for the treatment and prevention of infectious and proliferative diseases, including microbial infections and cancer.Type: ApplicationFiled: January 11, 2012Publication date: May 17, 2012Applicant: Biota Scientific Management Pty LtdInventors: Paula Francom, Barbara Frey, Silas Bond, Jianmin Duan, Richard Bethell, George Kukolj
-
Publication number: 20120116067Abstract: The invention relates to a method for producing phosphate-bridged nucleoside conjugates. In the method, a cyclosaligenyl nucleotide is produced first, to which a linker is added, which is used to perform the immobilization on a solid phase. A subsequent reaction with corresponding nucleophiles results in the desired phosphate-bridged nucleoside conjugates, which can then again be cleaved from the solid phase-bound linker.Type: ApplicationFiled: May 6, 2010Publication date: May 10, 2012Applicant: UNIVERSITAET HAMBURGInventors: Chris Meier, Viktoria Caroline Tonn
-
Patent number: 8158776Abstract: This invention is directed to a method of enhancing or facilitating the clearance or the lung mucus secretions in a subject. This invention is also directed to a method of facilitating the hydration of the lung mucus secretions in a subject. This invention is further directed to a method of preventing or treating diseases or conditions associated with impaired lung or airway function in a human or other mammal. The method comprises administering to a subject a pharmaceutical composition comprising a therapeutic effective amount of P2Y6 receptor agonist compound, wherein said amount is effective to activate the P2Y6 receptors on the luminal surface of lung epithelia. The P2Y6 receptor agonist compounds useful for this invention include mononucleoside 5?-diphosphates, dinucleoside monophosphate, dinucleoside diphosphates, or dinucleoside triphosphates of general Formula I, or salts, solvates, hydrates thereof. This invention is also directed to novel P2Y6 receptor agonist compounds.Type: GrantFiled: November 4, 2010Date of Patent: April 17, 2012Assignee: Inspire Pharmaceuticals, Inc.Inventors: José L. Boyer, Sammy R. Shaver, James G. Douglass, III, Catherine C. Redick
-
Publication number: 20120058469Abstract: The invention provides a novel class of cyanine dyes that are functionalized with a linker moiety that facilitates their conjugation to other species and substituent groups which increase the water-solubility, and optimize the optical properties of the dyes. Also provided are conjugates of the dyes, methods of using the dyes and their conjugates and kits including the dyes and their conjugates.Type: ApplicationFiled: August 25, 2011Publication date: March 8, 2012Applicant: Pacific Biosciences of California, Inc.Inventor: Gene Shen
-
Publication number: 20120040345Abstract: This disclosure provides novel reversibly terminated ribonucleotides which can be used as a reagent for DNA sequencing reactions. Methods of sequencing nucleic acids using the disclosed nucleotides are also provided.Type: ApplicationFiled: August 10, 2011Publication date: February 16, 2012Applicant: ALERE SAN DIEGO, INC.Inventors: Olaf Piepenburg, Derek L. Stemple, Niall A. Armes
-
Publication number: 20110300142Abstract: The invention relates to the use of 1-(?-D-Ribofuranosyl)-1,2-dihydropyrimidin-2-one derivative or mimetic or an analogue, derivatives, metabolites, variants or salts thereof for the manufacturing of a medicament to increase the amount of Indoleamine 2,3-dioxygenase (IDO) production in order to induce immunological tolerance as well as a method of treating a mammal in need thereof.Type: ApplicationFiled: May 26, 2008Publication date: December 8, 2011Inventors: Leif G. Salford, Bertil Persson, Hans Olov Sjögren, Bengt Widegren
-
Publication number: 20110257109Abstract: The present invention encompasses compositions and methods that activate P2Y receptors for the increased production of new synapses in the central nervous system. The formulations of the invention may be administered to a healthy subject or to a subject in need thereof to restore synapses.Type: ApplicationFiled: April 19, 2011Publication date: October 20, 2011Inventor: Richard WURTMAN
-
Publication number: 20110212437Abstract: Methods, Compositions, and Systems are provided for nucleic acid sequencing where the sequential incorporation of nucleotides uses two distinct chemical steps. A plurality of nucleotide analogs, each having a labeled leaving group at its 3? hydroxyl can be sequentially added to a growing strand in the presence of a selective cleaving activity that cleaves the 3? hydroxyl leaving group preferentially after it has been incorporated. The selective cleaving agent can comprise an exonuclease activity, and the exonuclease activity can be a polymerase-associated exonuclease activity. Nucleotide analogs having labels on both a cleavable polyphosphate portion and on a 3? hydroxyl leaving group can provide signals characteristic of nucleotide analog incorporation. Systems having illumination optics, collection optics, and substrates observe signals from the labels as they are being incorporated into a growing nucleic acid strand, allowing for the sequencing of template nucleic acids.Type: ApplicationFiled: February 8, 2011Publication date: September 1, 2011Applicant: Pacific Biosciences of California, Inc.Inventors: Robin Emig, Lei Jia, Jeremiah Hanes, Lubomir Sebo
-
Publication number: 20110177316Abstract: The invention relates to a method for producing a biodegradable molded part, comprising: providing a binding agent which contains a lyzable biopolymer; forming a molded part from the binding agent, wherein the time stability of the molded part to biological lysis is set by at least one of the following measures: adding a pulverized inorganic solid matter in a proportion of 5% to 85% of the mass of the binding agent before forming the molded part; thawing at least one of the surfaces of the molded part using a chemical or biological method such that the surface has a structuring in the range between 1 nm and 10 ?m. The invention further relates to an accordingly produced molded part.Type: ApplicationFiled: October 3, 2008Publication date: July 21, 2011Applicant: LEONARDIS-STIFTUNGInventors: Klaus Rennebeck, Bernd Hildenbrand
-
Publication number: 20110137023Abstract: The invention relates to a method for producing phosphate-bridged nucleoside conjugates. In the method a nucleophile is first dissolved in a non-aqueous solvent and dried, and a cyclosaligenyl phosphate compound is subsequently added to the solution.Type: ApplicationFiled: August 6, 2009Publication date: June 9, 2011Applicant: Universitaet HamburgInventors: Chris Meier, Saskia Wolf, Svenja Warnecke
-
Publication number: 20110053154Abstract: This disclosure provides novel reversibly terminated ribonucleotides which can be used as a reagent for DNA sequencing reactions. Methods of sequencing nucleic acids using the disclosed nucleotides are also provided.Type: ApplicationFiled: June 21, 2010Publication date: March 3, 2011Applicant: TwistDx, Inc.Inventors: Olaf Piepenburg, Derek L. Stemple, Niall A. Armes
-
Publication number: 20110046362Abstract: The invention provides compounds and methods for making adenosine-ribofuranoside tetraphosphate compounds. The compounds are contemplated to have activity at the P2Y receptor and may be used in the treatment of medical disorders such as cystic fibrosis and upper respiratory disorders.Type: ApplicationFiled: February 13, 2009Publication date: February 24, 2011Inventors: Carmen M. Baldino, Dan P. Cook, Shomir Ghosh, Lazlo Varady, Thomas Andreas Waldbach, Zhongguo Wang
-
Publication number: 20100316594Abstract: 2? and/or 3? prodrugs of 1?, 2?, 3? or 4?-branched nucleosides, and their pharmaceutically acceptable salts and derivatives are described. These prodrugs are useful in the prevention and treatment of Flaviviridae infections, including HCV infection, and other related conditions. Compounds and compositions of the prodrugs of the present invention are described. Methods and uses are also provided that include the administration of an effective amount of the prodrugs of the present invention, or their pharmaceutically acceptable salts or derivatives. These drugs may optionally be administered in combination or alteration with further anti-viral agents to prevent or treat Flaviviridae infections and other related conditions.Type: ApplicationFiled: June 2, 2008Publication date: December 16, 2010Inventors: Jean-Pierre Sommadossi, Paolo LaColla, Richard Storer, Gilles Gosselin
-
Publication number: 20100256086Abstract: The invention provides non-hydrolyzable nucleoside polyphosphate derivatives, e.g., 2MeS-adenosine-?,?-CH2-5?-O-(1-boranotriphosphate), 2MeS-adenosine-?,?-CCl2-5?-O-(1-boranotriphosphate), 2-MeS-adenosine-5?-dichloro methylene-diphosphate, 2-MeS-adenosine-5?-difluoromethylene-diphosphate and 2MeS-adenosine-5?-O-(1-boranodiphosphate), as well as pharmaceutical compositions thereof. These compounds are useful for prevention or treatment of diseases or disorders modulated by P2Y-receptors such as type 2 diabetes, and for pain control.Type: ApplicationFiled: November 23, 2008Publication date: October 7, 2010Applicant: BAR-ILAN UNIVETRSITYInventor: Bilha FISCHER
-
Publication number: 20090299048Abstract: This invention features bis-amides of pyrophosphoric acid and bisphosphonic acids, their preparation, and their use in synthesis of P1,P4-dinucleoside tetraphosphates, tetraphosphonates, and related compounds.Type: ApplicationFiled: July 23, 2007Publication date: December 3, 2009Applicant: GLSynthesis IncInventors: Ivan Yanachkov, George E. Wright
-
Publication number: 20090076256Abstract: The present invention relates to mononucleoside phosphate compounds that have the benefits of a dinucleotide pharmaceutical. These mononucleoside phosphates can be made from a mononucleotide that has been modified by attaching a degradation-resistant substituent on the terminal phosphate of a polyphosphate mononucleotide. By attaching this degradation-resistant substituent, the stability from degradation matches or exceeds those of certain dinucleotides. The mononucleoside phosphate compounds of the present invention are useful in preventing and treating epithelial tissue diseases or diseases or disorders associated with platelet aggregation.Type: ApplicationFiled: September 10, 2008Publication date: March 19, 2009Inventors: James G. Douglass, III, Benjamin R. Yerxa, Sammy R. Shaver, Ward M. Peterson, Edward G. Brown, Christopher S. Crean, Jose L. Boyer
-
Publication number: 20090047712Abstract: The present invention provides phosphoramidite linkers that are useful for the production of synthesizing two or more oligonucleotides in tandem. The inventive linkers have the following desirable properties: (i) enhanced stability to alkali conditions versus the linkers previously published, (ii) cleave to produce 5? and 3? ends that are fully biologically compatible, (iii) cleave completely under conditions that are already used in cleavage/deprotection processes so they are fully compatible with conditions that are common in laboratories and do not require additives that necessitate further purification after cleavage, (iv) integrate easily onto commercially available synthesizers because they are compatible with standard coupling chemistry, and (v) are compatible with DNA, RNA, forward, reverse, and synthesis chemistries. In addition, the inventive linkers may be coupled to a solid support. Thus, the inventive linkers provide a significant advancement in the state of the art.Type: ApplicationFiled: August 15, 2007Publication date: February 19, 2009Inventors: Keith Anderson, Michael Jensen, Ronald W. Davis
-
Publication number: 20090036666Abstract: The disclosed invention provides compositions and methods of treating a Flaviviridae infection, including hepatitis C virus, West Nile Virus, yellow fever virus, and a rhinovirus infection in a host, including animals, and especially humans, using a (2?R)-2?-deoxy-2?-fluoro-2?-C-methyl nucleosides, or a pharmaceutically acceptable salt or prodrug thereof.Type: ApplicationFiled: September 29, 2008Publication date: February 5, 2009Applicant: PHARMASSET, INC.Inventor: JEREMY CLARK
-
Publication number: 20090018324Abstract: Labeled nucleotide analogs used in place of naturally occurring nucleoside triphosphates or other analogs in template directed nucleic acid synthesis reactions and other nucleic acid reactions, and various analyses based thereon, including DNA sequencing, single base identification, hybridization assays and others.Type: ApplicationFiled: May 15, 2008Publication date: January 15, 2009Applicant: Pacific Biosciences of California, Inc.Inventors: Yue Xu, Jeffrey Wegener, Arek Bibillo
-
Patent number: 7476734Abstract: The invention provides nucleotide analogs for use in sequencing nucleic acid molecules.Type: GrantFiled: December 6, 2005Date of Patent: January 13, 2009Assignee: Helicos Biosciences CorporationInventor: David R. Liu